These findings of clinical benefit via atezolizumab in the immune cell PD-L1-high subgroup and in the patients with clear cell carcinoma are consistent with our results that response to nivolumab could be expected through elevated immunoreactivity and clear cell phenotype. This evidence concerns the gene CD274 and clear cell adenocarcinoma.